A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Conditions: Systemic Lupus Erythematosus (SLE); Immune-Mediated Necrotizing Myopathy; Neuromyelitis Optica Spectrum Disorders; Multiple Sclerosis-Relapsing-Remitting Interventions: Biological: CD20/BCMA-directed CAR-T cells Sponsors: RenJi Hospital; AbelZeta Pharma Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials